PTCT
PTC Therapeutics, Inc.$75.17+0.46 (+0.62%)Prev Close$74.71·MCap$6.11B·P/E8.58·Vol739.3K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
58
$45.52M
◆
Net Activity
Net Seller
$45.52M
●
Active Insiders
12
last 12 mo
Over the past 12 months, insider activity at PTC Therapeutics, Inc. (PTCT) has been exclusively selling, with 0 insider purchases totaling $0.00 and 58 insider sales totaling $45.52M. The most recent insider transaction was by Boulding Mark Elliott (officer: EXEC. VP AND CLO), who sold $203.0K worth of shares on May 19, 2026. PTC Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $6.11B.
PTCT Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 19, 2026 | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 2,812 | $72.18 | $203.0K | 105,668 |
| May 15, 2026 | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 12,572 | $72.95 | $917.2K | 405,891 |
| May 12, 2026 | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 3,540 | $78.97 | $279.6K | 107,112 |
| Apr 23, 2026 | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 2,850 | $70.91 | $202.1K | 394,070 |
| Apr 8, 2026 | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 2,265 | $69.45 | $157.3K | 106,655 |
| Apr 6, 2026 | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 829 | $67.99 | $56.4K | 79,115 |
| Mar 13, 2026 | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 2,662 | $64.08 | $170.6K | 396,920 |
| Mar 12, 2026 | Okey Stephanie | director | Sell | 14,000 | $70.00 | $980.0K | 8,000-64% |
| Mar 9, 2026 | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 3,989 | $63.38 | $252.8K | 2,737-59% |
| Mar 9, 2026 | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 10,000 | $63.38 | $633.8K | 79,944 |
| Mar 9, 2026 | Okey Stephanie | director | Sell | 6,333 | $63.38 | $401.4K | 8,000-44% |
| Feb 19, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 3,019 | $69.48 | $209.8K | 0 |
| Feb 18, 2026 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 3,121 | $69.36 | $216.5K | 0 |
| Feb 18, 2026 | Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER | Sell | 2,484 | $69.36 | $172.3K | 0 |
| Feb 18, 2026 | Gravier Pierre | CHIEF FINANCIAL OFFICER | Sell | 2,992 | $69.36 | $207.5K | 0 |
| Feb 18, 2026 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 7,371 | $69.36 | $511.3K | 0 |
| Feb 18, 2026 | Pauwels Eric | CHIEF BUSINESS OFFICER | Sell | 3,019 | $69.36 | $209.4K | 0 |
| Feb 18, 2026 | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,494 | $69.36 | $173.0K | 0 |
| Feb 17, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 5,894 | $69.33 | $408.6K | 0 |
| Jan 12, 2026 | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 940 | $76.45 | $71.9K | 115,196 |
| Jan 12, 2026 | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 6,347 | $77.06 | $489.1K | 115,177 |
| Jan 12, 2026 | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 866 | $76.45 | $66.2K | 92,428 |
| Jan 12, 2026 | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 2,514 | $76.45 | $192.2K | 394,453 |
| Jan 12, 2026 | Pauwels Eric | officer: CHIEF BUSINESS OFFICER | Sell | 7,348 | $77.02 | $565.9K | 84,928 |
| Jan 12, 2026 | Utter Christine Marie | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 1,034 | $76.45 | $79.0K | 72,693 |
| Jan 8, 2026 | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 2,411 | $77.19 | $186.1K | 117,103 |
| Jan 8, 2026 | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 6,618 | $77.31 | $511.6K | 119,162 |
| Jan 8, 2026 | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 1,982 | $77.12 | $152.9K | 93,936 |
| Jan 8, 2026 | Gravier Pierre | officer: CHIEF FINANCIAL OFFICER | Sell | 2,139 | $76.95 | $164.6K | 90,310 |
| Jan 8, 2026 | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 8,165 | $77.15 | $629.9K | 399,983 |
| Jan 8, 2026 | Pauwels Eric | officer: CHIEF BUSINESS OFFICER | Sell | 3,141 | $77.18 | $242.4K | 88,841 |
| Jan 8, 2026 | Utter Christine Marie | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,616 | $77.19 | $201.9K | 74,962 |
| Jan 6, 2026 | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 2,266 | $75.55 | $171.2K | 122,044 |
| Jan 6, 2026 | Reeve Emma | director | Sell | 734 | $76.00 | $55.8K | 10,666 |
| Jan 6, 2026 | STEELE GLENN JR MD PHD | director | Sell | 12,000 | $76.35 | $916.2K | 18,500-39% |
| Dec 23, 2025 | Pauwels Eric | CHIEF BUSINESS OFFICER | Sell | 20,508 | $77.26 | $1.58M | 88,678 |
| Dec 19, 2025 | Pauwels Eric | CHIEF BUSINESS OFFICER | Sell | 43,392 | $75.40 | $3.27M | 72,912-37% |
| Dec 5, 2025 | Reeve Emma | Sell | 733 | $78.62 | $57.6K | 6,666 | |
| Dec 3, 2025 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 3,428 | $79.07 | $271.1K | 349,964 |
| Nov 26, 2025 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 107,500 | $82.36 | $8.85M | 134,735-44% |
| Nov 26, 2025 | Jacobson Allan Steven | Sell | 26,000 | $82.00 | $2.13M | 22,891-53% | |
| Nov 25, 2025 | Reeve Emma | Sell | 10,000 | $79.50 | $795.0K | 6,666-60% | |
| Nov 19, 2025 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 2,812 | $75.99 | $213.7K | 104,870 |
| Nov 14, 2025 | Reeve Emma | Sell | 7,333 | $74.50 | $546.3K | 6,666-52% | |
| Oct 31, 2025 | Reeve Emma | Sell | 15,666 | $69.50 | $1.09M | 6,666-70% | |
| Oct 9, 2025 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 3,375 | $63.43 | $214.1K | 105,519 |
| Oct 7, 2025 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 55,000 | $66.05 | $3.63M | 128,764-30% |
| Oct 7, 2025 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 24,921 | $65.75 | $1.64M | 118,925 |
| Oct 7, 2025 | Jacobson Allan Steven | Sell | 12,000 | $65.00 | $780.0K | 17,451-41% | |
| Oct 7, 2025 | Reeve Emma | Sell | 25,562 | $65.96 | $1.69M | 17,304-60% |
Showing 1–50 of 187
1 / 4
PTCT Insider Buying Activity
The following table shows recent insider purchases of PTC Therapeutics, Inc. (PTCT) stock reported via SEC Form 4 filings.
No insider buying activity found for PTCT in the last 12 months.
PTCT Insider Selling Activity
The following table shows recent insider sales of PTC Therapeutics, Inc. (PTCT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 19, 2026 | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 2,812 | $72.18 | $203.0K | 105,668 |
| May 15, 2026 | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 12,572 | $72.95 | $917.2K | 405,891 |
| May 12, 2026 | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 3,540 | $78.97 | $279.6K | 107,112 |
| Apr 23, 2026 | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 2,850 | $70.91 | $202.1K | 394,070 |
| Apr 8, 2026 | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 2,265 | $69.45 | $157.3K | 106,655 |
| Apr 6, 2026 | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 829 | $67.99 | $56.4K | 79,115 |
| Mar 13, 2026 | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 2,662 | $64.08 | $170.6K | 396,920 |
| Mar 12, 2026 | Okey Stephanie | director | Sell | 14,000 | $70.00 | $980.0K | 8,000-64% |
| Mar 9, 2026 | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 3,989 | $63.38 | $252.8K | 2,737-59% |
| Mar 9, 2026 | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 10,000 | $63.38 | $633.8K | 79,944 |
| Mar 9, 2026 | Okey Stephanie | director | Sell | 6,333 | $63.38 | $401.4K | 8,000-44% |
| Feb 19, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 3,019 | $69.48 | $209.8K | 0 |
| Feb 18, 2026 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 3,121 | $69.36 | $216.5K | 0 |
| Feb 18, 2026 | Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER | Sell | 2,484 | $69.36 | $172.3K | 0 |
| Feb 18, 2026 | Gravier Pierre | CHIEF FINANCIAL OFFICER | Sell | 2,992 | $69.36 | $207.5K | 0 |
| Feb 18, 2026 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 7,371 | $69.36 | $511.3K | 0 |
| Feb 18, 2026 | Pauwels Eric | CHIEF BUSINESS OFFICER | Sell | 3,019 | $69.36 | $209.4K | 0 |
| Feb 18, 2026 | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,494 | $69.36 | $173.0K | 0 |
| Feb 17, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 5,894 | $69.33 | $408.6K | 0 |
| Jan 12, 2026 | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 940 | $76.45 | $71.9K | 115,196 |
| Jan 12, 2026 | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 6,347 | $77.06 | $489.1K | 115,177 |
| Jan 12, 2026 | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 866 | $76.45 | $66.2K | 92,428 |
| Jan 12, 2026 | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 2,514 | $76.45 | $192.2K | 394,453 |
| Jan 12, 2026 | Pauwels Eric | officer: CHIEF BUSINESS OFFICER | Sell | 7,348 | $77.02 | $565.9K | 84,928 |
| Jan 12, 2026 | Utter Christine Marie | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 1,034 | $76.45 | $79.0K | 72,693 |
| Jan 8, 2026 | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 2,411 | $77.19 | $186.1K | 117,103 |
| Jan 8, 2026 | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 6,618 | $77.31 | $511.6K | 119,162 |
| Jan 8, 2026 | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 1,982 | $77.12 | $152.9K | 93,936 |
| Jan 8, 2026 | Gravier Pierre | officer: CHIEF FINANCIAL OFFICER | Sell | 2,139 | $76.95 | $164.6K | 90,310 |
| Jan 8, 2026 | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 8,165 | $77.15 | $629.9K | 399,983 |
| Jan 8, 2026 | Pauwels Eric | officer: CHIEF BUSINESS OFFICER | Sell | 3,141 | $77.18 | $242.4K | 88,841 |
| Jan 8, 2026 | Utter Christine Marie | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,616 | $77.19 | $201.9K | 74,962 |
| Jan 6, 2026 | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 2,266 | $75.55 | $171.2K | 122,044 |
| Jan 6, 2026 | Reeve Emma | director | Sell | 734 | $76.00 | $55.8K | 10,666 |
| Jan 6, 2026 | STEELE GLENN JR MD PHD | director | Sell | 12,000 | $76.35 | $916.2K | 18,500-39% |
| Dec 23, 2025 | Pauwels Eric | CHIEF BUSINESS OFFICER | Sell | 20,508 | $77.26 | $1.58M | 88,678 |
| Dec 19, 2025 | Pauwels Eric | CHIEF BUSINESS OFFICER | Sell | 43,392 | $75.40 | $3.27M | 72,912-37% |
| Dec 5, 2025 | Reeve Emma | Sell | 733 | $78.62 | $57.6K | 6,666 | |
| Dec 3, 2025 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 3,428 | $79.07 | $271.1K | 349,964 |
| Nov 26, 2025 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 107,500 | $82.36 | $8.85M | 134,735-44% |
| Nov 26, 2025 | Jacobson Allan Steven | Sell | 26,000 | $82.00 | $2.13M | 22,891-53% | |
| Nov 25, 2025 | Reeve Emma | Sell | 10,000 | $79.50 | $795.0K | 6,666-60% | |
| Nov 19, 2025 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 2,812 | $75.99 | $213.7K | 104,870 |
| Nov 14, 2025 | Reeve Emma | Sell | 7,333 | $74.50 | $546.3K | 6,666-52% | |
| Oct 31, 2025 | Reeve Emma | Sell | 15,666 | $69.50 | $1.09M | 6,666-70% | |
| Oct 9, 2025 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 3,375 | $63.43 | $214.1K | 105,519 |
| Oct 7, 2025 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 55,000 | $66.05 | $3.63M | 128,764-30% |
| Oct 7, 2025 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 24,921 | $65.75 | $1.64M | 118,925 |
| Oct 7, 2025 | Jacobson Allan Steven | Sell | 12,000 | $65.00 | $780.0K | 17,451-41% | |
| Oct 7, 2025 | Reeve Emma | Sell | 25,562 | $65.96 | $1.69M | 17,304-60% |
PTCT Insiders
Similar Stocks to PTCT
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B